JP7524508B1 - Kallikrein 7 production promoter - Google Patents
Kallikrein 7 production promoter Download PDFInfo
- Publication number
- JP7524508B1 JP7524508B1 JP2023087365A JP2023087365A JP7524508B1 JP 7524508 B1 JP7524508 B1 JP 7524508B1 JP 2023087365 A JP2023087365 A JP 2023087365A JP 2023087365 A JP2023087365 A JP 2023087365A JP 7524508 B1 JP7524508 B1 JP 7524508B1
- Authority
- JP
- Japan
- Prior art keywords
- klk7
- kallikrein
- ergothioneine
- production promoter
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100034867 Kallikrein-7 Human genes 0.000 title claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- 101710176222 Kallikrein-7 Proteins 0.000 title claims abstract description 12
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 22
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000009759 skin aging Effects 0.000 claims description 2
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 230000036252 glycation Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 25
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 22
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101001091369 Mus musculus Kallikrein-7 Proteins 0.000 description 2
- 241000222350 Pleurotus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- -1 germicides Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000037012 chymotrypsin-like activity Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000055383 human KLK7 Human genes 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
【課題】新規なカリクレイン７の産生促進剤を提供すること。【解決手段】エルゴチオネインを含むカリクレイン７の産生促進剤。【選択図】図１The present invention provides a novel kallikrein 7 production promoter. The present invention provides a kallikrein 7 production promoter that contains ergothioneine. [Selected Figure] Figure 1
Description
本発明は、カリクレイン７の産生促進剤に関する。 The present invention relates to a kallikrein 7 production promoter.
カリクレイン７（Ｋａｌｌｉｋｒｅｉｎ ７）（以下、ＫＬＫ７ともいう。）は、キモトリプシン様活性を示すカリクレイン遺伝子ファミリーのＳ１セリンプロテアーゼである。ＫＬＫ７は、主として皮膚において発現し、皮膚生理に深く関与していることが知られている。本出願人は、特許文献１、２に、カリクレイン７産生促進剤を提案している。 Kallikrein 7 (hereinafter also referred to as KLK7) is an S1 serine protease of the kallikrein gene family that exhibits chymotrypsin-like activity. KLK7 is mainly expressed in the skin and is known to be deeply involved in skin physiology. The present applicant has proposed a kallikrein 7 production promoter in Patent Documents 1 and 2.
エルゴチオネイン（Ｅｒｇｏｔｈｉｏｎｅｉｎｅ）は、キノコ等の担子菌類等により生合成されるアミノ酸誘導体であり、ビタミンＣ、ビタミンＥよりも強い抗酸化力を有していることが知られている。また、エルゴチオネインは生理活性を有することも知られており、例えば、特許文献３には、エルゴチオネインを有効成分とするＡＴＰ産生促進剤、表皮細胞賦活剤、老化及び肌荒れ改善用皮膚外用剤が、特許文献４には、エルゴチオネインを有効成分とする血管壁強化剤が提案されている。 Ergothioneine is an amino acid derivative biosynthesized by basidiomycetes such as mushrooms, and is known to have stronger antioxidant power than vitamin C and vitamin E. Ergothioneine is also known to have physiological activity; for example, Patent Document 3 proposes an ATP production promoter, an epidermal cell activator, and an external skin preparation for improving aging and rough skin, each of which contains ergothioneine as an active ingredient, while Patent Document 4 proposes a vascular wall strengthening agent, each of which contains ergothioneine as an active ingredient.
本発明は、新規なカリクレイン７産生促進剤を提供することを課題とする。 The objective of the present invention is to provide a novel kallikrein 7 production promoter.
本発明の課題を解決するための手段は以下のとおりである。
１．エルゴチオネインを含むカリクレイン７の産生促進剤。
The means for solving the problems of the present invention are as follows.
1. A kallikrein 7 production promoter that contains ergothioneine.
本発明により、ＫＬＫ７の産生促進剤成物が提供される。 The present invention provides a KLK7 production promoter composition.
エルゴチオネインは、化学式Ｃ９Ｈ１５Ｎ３Ｏ２Ｓで表されるアミノ酸誘導体である。
エルゴチオネインとしては、タモギタケ等の担子菌類や酒粕等からの抽出物を用いることができ、これらの抽出物はそのまま、または精製して用いることができる。また、エルゴチオネインとして市販品を用いることもできる。
Ergothioneine is an amino acid derivative with the chemical formula C9H15N3O2S .
As ergothioneine, extracts from basidiomycetes such as Pleurotus cornucoides, sake lees, etc. can be used, and these extracts can be used as they are or after purification. In addition, commercially available ergothioneine products can also be used.
・カリクレイン７の産生促進剤
ヒトＫＬＫ７は、分子質量２７，５２５Ｄａの分泌タンパク質である。ＫＬＫ７の産生を促進することにより、皮膚内のＫＬＫ７量を増加させ、皮膚の老化を抑制することが期待できる。
本発明のＫＬＫ７の産生促進剤は、エルゴチオネインを含む。本発明のＫＬＫ７の産生促進剤におけるエルゴチオネインの配合量は、本発明の効果を奏する限り特に制限されないが、好ましくは全量に対するエルゴチオネインの濃度は、０．０００００１質量％以上９９．５質量％以下である。
- Kallikrein 7 Production Promoters Human KLK7 is a secretory protein with a molecular mass of 27,525 Da. By promoting the production of KLK7, it is expected that the amount of KLK7 in the skin will be increased and skin aging will be inhibited.
The KLK7 production promoter of the present invention contains ergothioneine. The amount of ergothioneine in the KLK7 production promoter of the present invention is not particularly limited as long as the effects of the present invention are achieved, but the concentration of ergothioneine relative to the total amount is preferably 0.000001% by mass or more and 99.5% by mass or less.
本発明のＫＬＫ７の産生促進剤は、本発明の効果を損なわない範囲内において、その剤形において一般的に用いられる植物油、動物油等の油性基剤、鎮痛消炎剤、鎮痛剤、殺菌消毒剤、収斂剤、ホルモン剤、ビタミン類、アルコール類、キレート剤、ｐＨ調整剤、防腐剤、増粘剤、色素、香料等を本発明の効果を妨害しない範囲で適宜配合することができる。
本発明のＫＬＫ７の産生促進剤は、経口投与、経皮投与のいずれも可能であり、化粧品、皮膚外用剤、医薬品、食品、飲料などとすることができる。本発明のＫＬＫ７の産生促進剤は、経皮投与することが好ましく、化粧品、皮膚外用剤、医薬品などのうち、水溶液状、クリーム状、ゲル状、ペースト状、固形状、エアゾール状、貼付剤状の経皮組成物の剤形を採用することが特に好ましい。
The KLK7 production promoter of the present invention can be appropriately formulated with oily bases such as vegetable oils and animal oils, analgesics and anti-inflammatory agents, analgesics, germicides, disinfectants, astringents, hormones, vitamins, alcohols, chelating agents, pH adjusters, preservatives, thickeners, colorants, fragrances, etc. that are commonly used in the dosage form, within a range that does not impair the effects of the present invention.
The KLK7 production promoter of the present invention can be administered orally or transdermally, and can be in the form of cosmetics, topical skin preparations, medicines, foods, beverages, etc. The KLK7 production promoter of the present invention is preferably administered transdermally, and among cosmetics, topical skin preparations, medicines, etc., it is particularly preferable to adopt the dosage form of a transdermal composition in the form of an aqueous solution, cream, gel, paste, solid, aerosol, or patch.
以下に試験例を示し、本発明の組成物の示す効果について具体的に説明する。
実験１「ヒト表皮角化細胞のＫＬＫ７産生促進」
ヒト表皮角化細胞を用い、ＫＬＫ７産生促進効果を確認した。
細胞は、ＮＨＥＫ－Ｎｅｏ（ヒト表皮角化細胞、新生児皮膚由来、Ｌｉｆｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｊａｐａｎ社製）を用いた。培養液は、ＥｐｉＬｉｆｅ（登録商標）Ｍｅｄｉｕｍ ｗｉｔｈ ６０μＭ Ｃａｌｃｉｕｍ（Ｌｉｆｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｊａｐａｎ社製）にＨｕｍｅｄｉａ－ＫＧ２増殖添加剤セット（倉敷紡績株式会社製）を加えた培地を用いた。
The effects of the composition of the present invention will be specifically described below with reference to test examples.
Experiment 1: "Promotion of KLK7 production in human epidermal keratinocytes"
The effect of promoting KLK7 production was confirmed using human epidermal keratinocytes.
The cells used were NHEK-Neo (human epidermal keratinocytes, derived from neonatal skin, manufactured by Life Technologies Japan). The culture medium used was EpiLife (registered trademark) Medium with 60 μM Calcium (manufactured by Life Technologies Japan) supplemented with Humedia-KG2 growth additive set (manufactured by Kurashiki Boseki Co., Ltd.).
Ｈｕｍｅｄｉａ－ＫＧ２添加ＥｐｉＬｉｆｅで培養したヒト表皮角化細胞を、２．２×１０４ｃｅｌｌｓ／ｃｍ２の細胞密度で６ｗｅｌｌ ｐｌａｔｅに播種して、３７℃５％ＣＯ２インキュベーターにて一晩培養した後、エルゴチオネイン（Ｃａｙｍａｎ Ｃｈｅｍｉｃａｌ社）を０．００００３～０．００２質量％で添加した。さらに３日間３７℃５％ＣＯ２インキュベーター中で培養し、細胞内外のタンパク質を回収した。ＢＣＡタンパク質アッセイ キット（Ｔｈｅｒｍｏ Ｆｉｓｈｅｒ Ｓｃｉｅｎｔｉｆｉｃ社）を使用し、タンパク量を一定にした後、ウェスタンブロット法でＫＬＫ７の発現量を測定した。ローディングコントロールとしてβ―アクチンを定量し、β―アクチンに対する相対値を算出した。定量に当たって、一次抗体にはＨｕｍａｎ／Ｍｏｕｓｅ Ｋａｌｌｉｋｒｅｉｎ７ Ａｎｔｉｂｏｄｙ（Ｒ＆Ｄ Ｓｙｓｔｅｍｓ社）およびβ－Ａｃｔｉｎ Ａｎｔｉｂｏｄｙ （Ｃ４）（Ｓａｎｔａ Ｃｒｕｚ社）を１０００倍希釈し、４℃冷蔵庫にて４８時間反応させた。洗浄後、２次抗体にはそれぞれＧｏａｔ ａｎｔｉ－Ｍｏｕｓｅ ＩｇＧ（Ｈ＋Ｌ）（Ｔｈｅｒｍｏ Ｆｉｓｈｅｒ Ｓｃｉｅｎｔｉｆｉｃ社）およびＲａｂｂｉｔ ａｎｔｉ－Ｇｏａｔ ＩｇＧ（Ｈ＋Ｌ）（Ｔｈｅｒｍｏ Ｆｉｓｈｅｒ Ｓｃｉｅｎｔｉｆｉｃ社）を１００００倍希釈し、室温で１時間反応させたのち、ＥＣＬＴＭ Ｗｅｓｔｅｒｎ Ｂｌｏｔｔｉｎｇ Ｄｅｔｅｃｔｉｏｎ Ｓｙｓｔｅｍ（Ｃｉｔｉｖａ社）を用いて検出した。エルゴチオネインを添加しないコントロールに対し、細胞内のＫＬＫ７量の相対値を図１に、細胞から分泌されたＫＬＫ７量の相対値を図２に示す。 Human epidermal keratinocytes cultured in EpiLife with Humedia-KG2 were seeded in a 6-well plate at a cell density of 2.2 x 10 4 cells/cm 2 and cultured overnight in a 37°C, 5% CO 2 incubator, after which ergothioneine (Cayman Chemical) was added at 0.00003-0.002% by mass. The cells were further cultured for 3 days in a 37°C, 5% CO 2 incubator, and intracellular and extracellular proteins were collected. The expression level of KLK7 was measured by Western blotting using a BCA protein assay kit (Thermo Fisher Scientific) after the protein amount was kept constant. β-actin was quantified as a loading control, and the relative value to β-actin was calculated. For quantification, primary antibodies Human/Mouse Kallikrein 7 Antibody (R&D Systems) and β-Actin Antibody (C4) (Santa Cruz) were diluted 1000-fold and reacted in a 4° C. refrigerator for 48 hours. After washing, Goat anti-Mouse IgG (H+L) (Thermo Fisher Scientific) and Rabbit anti-Goat IgG (H+L) (Thermo Fisher Scientific) were diluted 10,000 times as secondary antibodies, reacted at room temperature for 1 hour, and then detected using ECL TM Western Blotting Detection System (Citiva). The relative value of the amount of KLK7 in the cells compared to the control without ergothioneine is shown in Figure 1, and the relative value of the amount of KLK7 secreted from the cells is shown in Figure 2.
・結果
エルゴチオネインが、カリクレイン７の産生を促進することが確かめられた。
Results: It was confirmed that ergothioneine promotes the production of kallikrein 7.
実験２「エルゴチオネインによる頬の角層中のＫＬＫ７量の増大」
被験者１２名に表１に示す０．００００６質量％エルゴチオネイン（タモギタケから抽出精製された商品）含有製剤を、左右の頬部に１日２回朝晩塗布した。塗布開始前及び４週間後の頬部の角層を角層チェッカー（アサヒバイオメッド社）でテープストリッピング法により採取した。ガラスビーズとＬａｅｍｍｌｉ Ｂｕｆｆｅｒ（組成：０．０９ＭＴｒｉｓ－ＨＣｌ、ｐＨ６．８、３％ＳＤＳ、１０．３％Ｇｌｙｃｅｒｏｌ）５００μＬの入ったサンプルチューブに角層を採取した角層チェッカーを入れ、ビーズ式細胞破砕装置（株式会社トミー精工製）を用いて２８００ｒｐｍで１８０秒間ホモジナイズし、角層タンパクを抽出した。各サンプルのタンパク量はＢＣＡ ｐｒｏｔｅｉｎ Ａｓｓａｙ Ｋｉｔ（Ｔｈｅｒｍｏ Ｓｃｉｅｎｔｉｆｉｃ社）で測定し、角層タンパク量を一定にした後、ウェスタンブロット法でＫＬＫ７の発現量を測定した。定量に当たって、一次抗体にはＨｕｍａｎ／Ｍｏｕｓｅ Ｋａｌｌｉｋｒｅｉｎ７ Ａｎｔｉｂｏｄｙ（Ｒ＆Ｄ Ｓｙｓｔｅｍｓ社）を３０００倍希釈し、４℃冷蔵庫にて１８時間反応させた。洗浄後、２次抗体にはＧｏａｔ ａｎｔｉ－Ｍｏｕｓｅ ＩｇＧ（Ｈ＋Ｌ）（Ｔｈｅｒｍｏ Ｆｉｓｈｅｒ Ｓｃｉｅｎｔｉｆｉｃ社）を１００００倍希釈し、室温で１時間反応させたのち、ＥＣＬＴＭ Ｗｅｓｔｅｒｎ Ｂｌｏｔｔｉｎｇ Ｄｅｔｅｃｔｉｏｎ Ｓｙｓｔｅｍ（Ｃｉｔｉｖａ社）を用いて検出した。塗布開始前に対する４週間後のＫＬＫ７産生量の相対値を図３に示す。
Experiment 2: "Ergothioneine increases KLK7 levels in the stratum corneum of the cheek"
A preparation containing 0.00006% by mass of ergothioneine (a product extracted and purified from Pleurotus corneum) shown in Table 1 was applied twice a day, morning and evening, to the left and right cheeks of 12 subjects. The stratum corneum of the cheeks was collected by tape stripping using a stratum corneum checker (Asahi Biomed Co., Ltd.) before and 4 weeks after the start of application. The stratum corneum checker with the collected stratum corneum was placed in a sample tube containing glass beads and 500 μL of Laemmli Buffer (composition: 0.09 M Tris-HCl, pH 6.8, 3% SDS, 10.3% glycerol), and homogenized at 2800 rpm for 180 seconds using a bead-type cell disrupter (Tomy Seiko Co., Ltd.) to extract stratum corneum proteins. The protein amount of each sample was measured using a BCA Protein Assay Kit (Thermo Scientific), and after the amount of stratum corneum protein was kept constant, the expression amount of KLK7 was measured by Western blotting. For the quantification, Human/Mouse Kallikrein7 Antibody (R&D Systems) was diluted 3000-fold as the primary antibody and reacted in a refrigerator at 4°C for 18 hours. After washing, Goat anti-Mouse IgG (H+L) (Thermo Fisher Scientific) was diluted 10,000 times as the secondary antibody, and reacted at room temperature for 1 hour, and then detected using ECL ™ Western Blotting Detection System (Citiva). The relative value of the amount of KLK7 produced 4 weeks after the start of application to that before the start of application is shown in FIG. 3.
・結果
エルゴチオネインを含む製剤を頬に塗布することにより、塗布前と比較して頬の角層中のＫＬＫ７量が増大した。カリクレイン７の産生が促進したと考えられる。
Results: By applying a formulation containing ergothioneine to the cheek, the amount of KLK7 in the stratum corneum of the cheek increased compared to before application. It is believed that the production of kallikrein 7 was promoted.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023087365A JP7524508B1 (en) | 2023-05-29 | 2023-05-29 | Kallikrein 7 production promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023087365A JP7524508B1 (en) | 2023-05-29 | 2023-05-29 | Kallikrein 7 production promoter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP7524508B1 true JP7524508B1 (en) | 2024-07-30 |
Family
ID=91967713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023087365A Active JP7524508B1 (en) | 2023-05-29 | 2023-05-29 | Kallikrein 7 production promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7524508B1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002037724A (en) | 2000-06-26 | 2002-02-06 | L'oreal Sa | Use of ergothioneine and/or its derivative as glycating agent |
| JP2009275027A (en) | 2008-04-17 | 2009-11-26 | Atsushi Hashimoto | Agent for hair |
| JP2012092085A (en) | 2010-09-28 | 2012-05-17 | Oriza Yuka Kk | Anti-skin photoaging agent using coprinus comatus and extract thereof |
| JP2016003198A (en) | 2014-06-16 | 2016-01-12 | 株式会社ファンケル | Kallikrein 7 production promoter |
| JP2018131405A (en) | 2017-02-15 | 2018-08-23 | 株式会社ファンケル | Kallikrein 7 production-promoting composition |
-
2023
- 2023-05-29 JP JP2023087365A patent/JP7524508B1/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002037724A (en) | 2000-06-26 | 2002-02-06 | L'oreal Sa | Use of ergothioneine and/or its derivative as glycating agent |
| JP2009275027A (en) | 2008-04-17 | 2009-11-26 | Atsushi Hashimoto | Agent for hair |
| JP2012092085A (en) | 2010-09-28 | 2012-05-17 | Oriza Yuka Kk | Anti-skin photoaging agent using coprinus comatus and extract thereof |
| JP2016003198A (en) | 2014-06-16 | 2016-01-12 | 株式会社ファンケル | Kallikrein 7 production promoter |
| JP2018131405A (en) | 2017-02-15 | 2018-08-23 | 株式会社ファンケル | Kallikrein 7 production-promoting composition |
Non-Patent Citations (2)
| Title |
|---|
| 岡野由利，希少アミノ酸エルゴチオネインは皮膚の老化を抑制する，FRAGRANCE JOURNAL，2008年03月， p.81-85 |
| 日本皮膚科学会雑誌, 2016.05, Vol.126, No.5, p.932 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6609401B2 (en) | Kallikrein 7 production promoter | |
| JP5677768B2 (en) | External composition for skin containing vitamins | |
| JP7524508B1 (en) | Kallikrein 7 production promoter | |
| KR102011669B1 (en) | A cosmetic composition using antimicrobial peptide for anti-acne | |
| JP3508042B2 (en) | Ceramide synthesis promoter | |
| JP2006290873A (en) | Aquaporin expression promoter | |
| JP5997822B1 (en) | External preparation for skin, anti-glycation agent and collagenase inhibitor | |
| KR101945349B1 (en) | Cosmetic composition comprising substance P for improving skin wrinkles or anti-inflammation activity | |
| JP2988803B2 (en) | Skin aging prevention cosmetic composition | |
| JP6580342B2 (en) | Tropoelastin expression promoter and elastin production promoter | |
| JP5255919B2 (en) | Collagen production promoter | |
| JP6370094B2 (en) | Composition for suppressing yellowing of skin | |
| JP2009184960A (en) | Skin bleaching cosmetic | |
| JP2022501372A (en) | Iron chelate compounds for treating aesthetic skin conditions | |
| KR20090113614A (en) | Cosmetic composition comprising retinol derivatives | |
| US20150152101A1 (en) | Active compounds for combating greasy skin | |
| TWI780699B (en) | Lactoferrin, derived peptides thereof and a use thereof for inhibiting and/or alleviating lipid synthesis | |
| KR102540969B1 (en) | Composition for promoting skin-regeneration containing sodium 2-mercaptoethane sulfonate | |
| US20230002449A1 (en) | Derived peptide of lactoferrin and method thereof for promoting and/or increasing lipid synthesis | |
| JP5527917B2 (en) | Arginase activity promoter and skin external preparation containing the same | |
| AU627725B2 (en) | Topical preparations | |
| JP3218282B2 (en) | Epidermal keratinization accelerator, cosmetic, and bath agent | |
| US20210137809A1 (en) | Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p | |
| JP2024130747A (en) | Skin barrier function improver | |
| JP2004534070A (en) | Use of at least one 10-hydroxy-2-decenoic acid derivative in a composition for treating the signs of skin aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240122 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240122 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240515 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240515 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240618 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240619 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7524508 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |